先端がん治療研究所 2018年度-

研究業績情報

論文

• Application of personal health record in enhancing the quality of life in patients with breast cancer who received adjuvant hormonal therapy., TAKADA Fuka;OKUYAMA Hiromi;中村　清吾;FUJITA Ken-ichi, Eur J Breast Health, :e, 2022年02月, 原著, 査読あり
• 乳がんに対する薬物療法の最前線, 鶴谷　純司, 昭和学士会雑誌, 81(3):162 - 165, 2021年08月, その他, 査読あり
• Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells., MATSUNAGA Yuki;YAMAOKA Toshimitsu;OHBA Motoi;MIURA Sakiko;MASUDA Hiroko;SANGAI Takafumi;TAKIMOTO Masafumi;NAKAMURA Seigo;TSURUTANI Junji, Antibodies (Basel), 10(1):6, 2021年02月, 原著, 査読あり
• Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis., ANDO Koichi;MANABE Ryo;KISHINO Yasunari;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori, Curr Oncol, 28(2):1094 - 1113, 2021年02月, 総説, 査読あり
• Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury., OHMORI Tohru;YAMAOKA Toshimitsu;ANDO Koichi;KUSUMOTO Sojiro;KISHINO Yasunari;MANABE Ryo;SAGARA Hironori, Int J Mol Sci, 22(2):792, 2021年01月, 総説, 査読あり
• Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations., KO Ryo;SHUKUYA Takehito;IMAMURA Chiyo K.;TOKITO Takaaki;SHIMADA Naoko;KOYAMA Ryo;YAMADA Kazuhiko;ISHII Hidenobu;AZUMA Koichi;TAKAHASHI Kazuhisa, Transl Lung Cancer Res, 10(1):183 - 192, 2021年01月, 原著, 査読あり
• Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis., AOGI Kenjiro;TAKEUCHI Hideki;SAEKI Toshiaki;AIBA Keisuke;TAMURA Kazuo;IINO Keiko;IMAMURA Chiyo K.;OKITA Kenji;KAGAMI Yoshikazu;TANAKA Ryuhei;NAKAGAWA Kazuhiko;FUJII Hirofumi;BOKU Narikazu;WADA Makoto;AKECHI Tatsuo;IIHARA Hirotoshi;OHTANI Shoichiro;OKUYAMA Ayako;OZAWA Keiko;KIM Yong-II;SASAKI Hidenori;SHIMA Yasuo;TAKEDA Masayuki;NAGASAKI Eijiro;NISHIDATE Toshihiko;HIGASHI Takehiro;HIRATA Kouichi, Int J Clin Oncol, 26(1):1 - 17, 2021年01月, 原著, 査読あり
• BRCAness as a prognostic indicator in patients with early breast cancer., LIU Lei;MATSUNAGA Yuki;TSURUTANI Junji;AKASHI-TANAKA Sadako;MASUDA Hiroko;IDE Yoshimi;HASHIMOTO Rikako;INUZUKA Mayuko;WATANABE Chie;TARUNO Kanae;SAWADA Terumasa;OKUYAMA Hiromi;ATA Arisa;KUWAYAMA Takashi;NAKAYAMA Sayuka;TONOUCHI Yumi;NAKAMURA Seigo, Sci Rep, 10(1):21173, 2020年12月, 原著, 査読あり
• Prospective evaluation and refinement of an S-1 dosage formula based on renal function for clinical application., TAKEUCHI Masashi;IMAMURA Chiyo K.;BOOKA Eisuke;TAKEUCHI Hiroya;MIZUKAMI Takuro;KAWAKAMI Takeshi;FUNAKOSHI Taro;WAKUDA Kazushige;AOKI Yu;HAMAMOTO Yasuo;KITAGO Minoru;KAWAKUBO Hirofumi;BOKU Narikazu;TANIGAWARA Yusuke;KITAGAWA Yuko, Cancer Sci, :e, 2020年12月, 原著, 査読あり
• Pharmacokinetics, Efficacy and Safety of Bosutinib in a Pediatric Patient With Chronic Myeloid Leukemia., INOUE Akiko;IMAMURA Chiyo K.;SHIMADA Hiroyuki;KATAYAMA Daisuke;URABE Keisuke;SUZUKI Ryo;TAKITANI Kimitaka;ASHIDA Akira, J Pediatr Pharmacol Ther, 25(8):742 - 745, 2020年11月, 原著, 査読あり
• HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer., YAMAOKA Toshimitsu;TSURUTANI Junji;SAGARA Hironori;OHMORI Tohru, Transl Lung Cancer Res, 9(5):2178 - 2183, 2020年10月, その他, 査読なし
• Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis., ANDO Koichi;KISHINO Yasunari;HOMMA Tetsuya;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;OHNISHI Tsukasa;SAGARA Hironori, Cancers (Basel), 12(7):1905, 2020年07月, 総説, 査読あり
• Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group., HIRATA Kenro;HAMAMOTO Yasuo;ANDO Masahiko;IMAMURA Chiyo K.;YOSHIMURA Kenichi;YAMAZAKI Kentaro;HIRONAKA Shuichi;MURO Kei, BMC Cancer, 20(1):548, 2020年06月, 原著, 査読あり
• HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers., LI Bob T.;MICHELINI Flavia;MISALE Sandra;COCCO Emiliano;BALDINO Laura;CAI Yanyan;SHIFMAN Sophie;TU Hai-Yan;MYERS Mackenzie L.;XU Chongrui;MATTAR Marissa;KHODOS Inna;LITTLE Megan;QERIQI Besnik;WEITSMAN Gregory;WILHEM Clare J.;LALANI Alshad S.;DIALA Irmina;FREEDMAN Rachel A.;LIN Nancy U.;SOLIT David B.;BERGER Michael F.;BARBER Paul R.;NG Tony;OFFIN Michael;ISBELL James M.;JONES David R.;Yu Helena A.;THYPARAMBIL Sheeno;LIAO Wei-Li;BHALKIKAR Anuja;CECCHI Fabiola;HYMAN David M.;LEWIS Jason S.;BUONOCORE Darren J.;HO Alan L.;MAKKER Vicky;REIS-FILHO Jorge S.;RAZAVI Pedram;ARCILA Maria E.;KRIS Mark G.;POIRIER John T.;SHEN Ronglai;TSURUTANI Junji;ULANER Gary A.;DE STANCHINA Elisa;ROSEN Neal;RUDIN Charles M.;SCALTRITI Maurizio, Cancer Discov, 10(5):674 - 687, 2020年05月, 原著, 査読あり
• Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors., TSURUTANI Junji;IWATA Hiroji;KROP Ian;JÄNNE Pasi A;DOI Toshihiko;TAKAHASHI Shunji;PARK Haeseong;REDFERN Charles;TAMURA Kenji;WISE-DRAPER Trisha M;SAITO Kaku;SUGIHARA Masahiro;SINGH Jasmeet;JIKOH Takahiro;GALLANT Gilles;LI Bob T, Cancer Discov, 10(5):688 - 701, 2020年05月, 原著, 査読あり
• The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition., SHIMOI Tatsunori;NAGAI Shigenori E;YOSHINAMI Tetsuhiro;TAKAHASHI Masato;ARIOKA Hitoshi;ISHIHARA Mikiya;KIKAWA Yuichiro;KOIZUMI Kei;KONDO Naoto;SAGARA Yasuaki;TAKADA Masahiro;TAKANO Toshimi;TSURUTANI Junji;NAITO Yoichi;NAKAMURA Rikiya;HATTORI Masaya;HARA Fimikata;HAYASHI Naoki;MIZUNO Toshiro;MIYASHITA Minoru;YAMASHITA Nami;YAMANAKA Takashi;SAJI Shigehira;IWATA Hiroji;TOYAMA Tatsuya, Breast Cancer, 27(3):322 - 331, 2020年05月, 原著, 査読あり
• 化学療法誘発性末梢神経障害を有する乳がん患者に対するハンドセラピー施術後の改善効果の検討, 佐々木　晶子;池田　明子;角田　ゆう子;澤田　晃暢;鶴谷　純司;辰尾　秋斗;木内　祐二;中村　清吾, 癌と化学療法, 47(5):783 - 788, 2020年05月, 原著, 査読あり
• A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide., MATSUMOTO Koji;TAKAHASHI Masato;SATO Kazuhiko;OSAKI Akihiko;TAKANO Toshimi;NAITO Yoichi;MATSUURA Kazuo;AOGI Kenjiro;FUJIWARA Kimiko;TAMURA Kenji;BABA Motoi;TOKUNAGA Shinya;HIRANO Gen;IMOTO Shigeru;MIYAZAKI Chieko;YANAGIHARA Kazuhiro;IMAMURA Chiyo K.;CHIBA Yasutaka;SAEKI Toshiaki, Cancer Med, 9(10):3319 - 3327, 2020年05月, 原著, 査読あり
• 小児がん治療における臨床薬理, 今村　知世, 小児外科, 52(5):454 - 459, 2020年05月, その他, 査読なし
• Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis., ANDO Koichi;AKIMOTO Kaho;SATO Hiroki;MANABE Ryo;KISHINO Yasunari;HOMMA Tetsuya;KUSUMOTO Sojiro;YAMAOKA Toshimitsu;TANAKA Akihiko;OHMORI Tohru;SAGARA Hironori, Cancers (Basel), 12(4):942, 2020年04月, 総説, 査読あり
• Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity., KAWAMURA Takahisa;IMAMURA Chiyo K.;KENMOTSU Hirotsugu;TAIRA Tetsuhiko;OMORI Shota;NAKASHIMA Kazuhisa;WAKUDA Kazushige;ONO Akira;NAITO Tateaki;MURAKAMI Haruyasu;MUSHIRODA Taisei;TAKAHASHI Toshiaki;TANIGAWARA Yusuke, Cancer Chemother Pharmacol, 85(3):605 - 614, 2020年03月, 原著, 査読あり
• Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer., MODI Shanu;SAURA Cristina;YAMASHITA Toshinari;PARK Yeon Hee;KIM Sung-Bae;TAMURA Kenji;ANDRE Fabrice;IWATA Hiroji;ITO Yoshinori;TSURUTANI Junji;SOHN Joohyuk;DENDULURI Neelima;PERRIN Christophe;AOGI Kenjiro;TOKUNAGA Eriko;IM Seock-Ah;LEE Keun Seok;HURVITZ Sara A;CORTES Javier;LEE Caleb;CHEN Shuquan;ZHANG Lin;SHAHIDI Javad;YVER Antoine;KROP Ian;DESTINY-Breast01 Investigators, N Engl J Med, 382(7):610 - 621, 2020年02月, 原著, 査読あり
• Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study., MODI Shanu;PARK Haeseong;MURTHY Rashmi K;IWATA Hiroji;TAMURA Kenji;TSURUTANI Junji;MORENO-ASPITIA Alvaro;DOI Toshihiko;SAGARA Yasuaki;REDFERN Charles;KROP Ian E;LEE Caleb;FUJISAKI Yoshihiko;SUGIHARA Masahiro;ZHANG Lin;SHAHIDI Javad;TAKAHASHIi Shunji, J Clin Oncol, :JCO1902318, 2020年02月, 原著, 査読あり
• High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer., OHKUMA Ryotaro;YADA Erica;ISHIKAWA Shumpei;KOMURA Daisuke;ISHIZAKI Hidenobu;TAMADA Koji;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;ONOUE Rie;ANDO Kiyohiro;TSURUTANI Junji;YOSHIMURA Kiyoshi;YOKOBORI Takehiko;SASADA Tetsuro;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;IZUMIZAKI Masahiko;KOBAYASHI Shinichi;TSUNODA Takuya;WADA Satoshi, PloS One, 15(1):e0226707, 2020年01月, 原著, 査読あり
• U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation., HARATANI Koji;YONESAKA Kimio;TAKAMURA Shiki;MAENISHI Osamu;KATO Ryoji;TAKEGAWA Naoki;KAWAKAMI Hisato;TANAKA Kaoru;HAYASHI Hidetoshi;TAKEDA Masayuki;MAEDA Naoyuki;KAGARI Takashi;HIROTANI Kenji;TSURUTANI Junji;NISHIO Kazuto;DOI Katsumi;MIYAZAWA Masaaki;NAKAGAWA Kazuhiko, J Clin Invest, 130(1):374 - 388, 2020年01月, 原著, 査読あり
• Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting., INOUE Kenichi;TAKAHASHI Masato;MUKAI Hirofumi;YAMANAKA Takashi;EGAWA Chiyomi;SAKATA Yukinori;IKEZAWA Hiroki;MATSUOKA Toshiyuki;TSURUTANI Junji, Invest New Drugs, :e, 2020年01月, 原著, 査読あり
• [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification., TAKEGAWA Naoki;TSURUTANI Junji;KAWAKAMI Hisato;YONESAKA Kimio;KATO Ryoji;HARATANI Koji;HAYASHI Hidetoshi;TAKEDA Masayuki;NONAGASE Yoshikane;MAENISHI Osamu;NAKAGAWA Kazuhiko, Int J Cancer, 145(12):3414 - 3424, 2019年12月, 原著, 査読あり
• Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer., YOSHIOKA Hiroshige;SHIMOKAWA Mototsugu;SETO Takashi;MORITA Satoshi;YATABE Yasushi;OKAMOTO Isamu;TSURUTANI Junji;SATOUCHI Miyako;HIRASHIMA Tomonori;ATAGI Shinji;SHIBATA Kazuhiko;SAITO Hiroshi;TOYOOKA Shinichi;YAMAMOTO Nobuyuki;NAKAGAWA Kazuhiko;MITSUDOMI Tetsuya, Ann Oncol, 30(12):1978 - 1984, 2019年12月, 原著, 査読あり
• CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study., TAMURA Kenji;IMAMURA Chiyo K.;TAKANO Toshimi;SAJI Shigehira;YAMANAKA Takeharu;YONEMORI Kan;TAKAHASHI Masato;TSURUTANI Junji;NISHIMURA Reiki;SATO Kazuhiko;KITANI Akira;UENO Naoto T.;MUSHIRODA Taisei;KUBO Michiaki;FUJIWARA Yasuhiro;TANIGAWARA Yusuke, J Clin Oncol, :JCO1901412, 2019年12月, 原著, 査読あり
• Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer., IWASA Tsutomu;TSURUTANI Junji;WATANABE Satomi;KATO Ryoji;MIZUNO Yutaka;KOJIMA Yasuyuki;TAKASHIMA Tsutomu;MATSUNAMI Nobuki;MORIMOTO Takashi;YAMAMURA Jun;OHTANI Shoichiro;TANABE Yuko;YOSHINAMI Tetsuhiro;TAKANO Toshimi;KOMOIKE Yoshifumi;NAKAGAWA Kazuhiko, BMC Cancer, 19(1):962, 2019年10月, 原著, 査読あり
• Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study., YAMAZAKI Kentaro;MATSUMOTO Shigemi;IMAMURA Chiyo K.;YAMAGIWA Chiemi;SHIMIZU Ayaka;YOSHINO Takayuki, Jpn J Clin Oncol, :e, 2019年10月, 原著, 査読あり
• A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)., SUZUKI Takeshi;SUKAWA Yasutaka;IMAMURA Chiyo K.;MASUISHI Toshiki;SATAKE Hironaga;KUMEKAWA Yosuke;FUNAKOSHI Shinsuke;KOTAKA Masahito;HORIE Yoshiki;KAWAI Sadayuki;OKUDA Hiroyuki;TERAZAWA Tetsuji;KONDOH Chihiro;KATO Ken;YOSHIMURA Kenichi;ISHIKAWA Hideki;HAMAMOTO Yasuo;BOKU Narikazu;TAKAISHI Hiromasa;KANAI Takanori, Clin Colorectal Cancer, :e, 2019年10月, 原著, 査読あり
• Differences in perception of breast cancer treatment between patients, physicians, and nurses and unmet information needs in Japan, SAKAI Haruna;UMEDA Megumi;OKUYAMA Hiromi;NAKAMURA Seigo, Support Care Cancer, :e, 2019年09月, 原著, 査読あり
• Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors, ANDO Kiyohiro;HAMADA Kazuyuki;WATANABE Makoto;OHKUMA Ryotaro;SHIDA Midori;ONOUE Rie;KUBOTA Yutaro;MATSUI Hiroto;ISHIGURO Tomoyuki;HIRASAWA Yuya;ARIIZUMI Hirotsugu;TSURUTANI Junji;YOSHIMURA Kiyoshi;TSUNODA Takuya;KOBAYASHI Shinichi;WADA Satoshi, Anticancer Res, 39(9):5195 - 5201, 2019年09月, 原著, 査読あり
• Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury., YAMAOKA Toshimitsu;ARATA Satoru;HOMMA Mayumi;HOMMA Tetsuya;KUSUMOTO Sojiro;ANDO Koichi;MANABE Ryo;KISHINO Yasunari;OHBA Motoi;TSURUTANI Junji;TAKIMOTO Masafumi;OHMORI Tohru;SAGARA Hironori, Int J Mol Sci, 20(16):E4021, 2019年08月, 原著, 査読あり
• The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV., AKAMATSU Hiroaki;NINOMIYA Kiichiro;KENMOTSU Hirotsugu;MORISE Masahiro;DAGA Haruko;GOTO Yasushi;KOZUKI Toshiyuki;MIURA Satoru;SASAKI Takaaki;TAMIYA Akihiro;TERAOKA Shunsuke;TSUBATA Yukari;YOSHIOKA Hiroshige;HATTORI Yoshihiro;IMAMURA Chiyo K.;KATSUYA Yuki;MATSUI Reiko;MINEGISHI Yuji;MIZUGAKI Hidenori;NOSAKI Kaname;OKUMA Yusuke;SAKAMOTO Setsuko;SONE Takashi;TANAKA Kentaro;UMEMURA Shigeki;YAMANAKA Takeharu;AMANO Shinsuke;HASEGAWA Kazuo;MORITA Satoshi;NAKAJIMA Kazuko;MAEMONDO Makoto;SETO Takashi;YAMAMOTO Nobuyuki, Int J Clin Oncol, 24(7):731 - 770, 2019年07月, 原著, 査読あり
• Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib., YAMAOKA Toshimitsu;OHBA Motoi;MATSUNAGA Yuki;TSURUTANI Junji;OHMORI Tohru, J Vis Exp, (148):e, 2019年06月, 原著, 査読あり
• Elucidation of carcinogenesis mechanism in chronic obstructive pulmonary disease (COPD) combined lung cancer., YAMAOKA Toshimitsu, Impact, 2019(6):23 - 25, 2019年06月, その他, 査読なし
• Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study., TAMURA Kenji;TSURUTANI Junji;TAKAHASHI Shunji;IWATA Hiroji;KROP Ian E;REDFERN Charles;SAGARA Yasuaki;DOI Toshihiko;PARK Haeseong;MURTHY Rashmi K;REDMAN Rebecca A;JIKOH Takahiro;LEE Caleb;SUGIHARA Masahiro;SHAHIDI Javad;YVER Antoine;MODI Shanu, Lancet Oncol, 20(6):816 - 826, 2019年06月, 原著, 査読あり
• Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study., SHITARA Kohei;IWATA Hiroji;TAKAHASHI Shunji;TAMURA Kenji;PARK Haeseong;MODI Shanu;TSURUTANI Junji;KADOWAKI Shigenori;YAMAGUCHI Kensei;IWASA Satoru;SAITO Kaku;FUJISAKI Yoshihiko;SUGIHARA Masahiro;SHAHIDI Javad;DOI Toshihiko, Lancet Oncol, 20(6):827 - 836, 2019年06月, 原著, 査読あり
• Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer., WATANABE Satomi;YONESAKA Kimio;TANIZAKI Junko;NONAGASE Yoshikane;TAKEGAWA Naoki;HARATANI Koji;KAWAKAMI Hisato;HAYASHI Hidetoshi;TAKEDA Masayuki;TSURUTANI Junji;NAKAGAWA Kazuhiko, Cancer Med, 8(3):1258 - 1268, 2019年03月, 原著, 査読あり
• Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study., TSURUTANI Junji;SAKATA Yukinori;MATSUOKA Toshiyuki, Breast Cancer, 26(2):235 - 243, 2019年03月, 原著, 査読あり
• KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR., NAKATANI Kaori;YAMAOKA Toshimitsu;OHBA Motoi;FUJITA Ken-ichi;ARATA Satoru;KUSUMOTO Sojiro;TAKI (TAKEMOTO) Iori;KAMEI Daisuke;IWAI Shinichi;TSURUTANI Junji;OHMORI Tohru, Mol Cancer Ther, 18(1):112 - 126, 2019年01月, 原著, 査読あり
• Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer., WATANABE Satomi;HAYASHI Hidetoshi;HARATANI Koji;SHIMIZU Shigeki;TANIZAKI Junko;SAKAI Kazuko;KAWAKAMI Hisato;YONESAKA Kimio;TSURUTANI Junji;TOGASHI Yosuke;NISHIO Kazuto;ITO Akihiko;NAKAGAWA Kazuhiko, Cancer Sci, 110(1):52 - 60, 2019年01月, 原著, 査読あり
• Receptor Tyrosine Kinase-Targeted Cancer Therapy., YAMAOKA Toshimitsu;KUSUMOTO Sojiro;ANDO Koichi;OHBA Motoi;OHMORI Tohru, Int J Mol Sci, 19(11):E3491, 2018年11月, 総説, 査読あり

講演・口頭発表等

• EGFR遺伝子変異を有する肺腺癌細胞PC-9における第３世代EGFR-TKI, オシメルチニブの獲得耐性機序の検討, 山岡　利光;岸野　康成;楠本　壮二郎;安藤　浩一;大森　亨;相良　博典;鶴谷　純司, 第62回日本肺癌学会学術集会, 2021年11月27日, 横浜・LIVE配信・オンデマンド配信
• Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for ES-SCLC, 安藤　浩一;岸野　康成;楠本　壮二郎;山岡　利光;田中　明彦;大森　亨;相良　博典, 第62回日本肺癌学会学術集会, 2021年11月27日, 横浜およびWEB配信
• 肺腺癌細胞PC-9における第3世代EGFR-TKI,オシメルチニブの獲得耐性機序の検討, 山岡　利光;岸野　康成;楠本　壮二郎;安藤　浩一;大森　亨;相良　博典;鶴谷　純司, 第80回⽇本癌学会学術総会, 2021年10月02日, 横浜
• 抗PD-1抗体で発症せず、抗PD-L1抗体投与後に血球貪食症候群様の免疫関連有害事象を発症した肺癌症例, 有泉　裕嗣;吉村　清;堀池　篤;平澤　優弥;石黒　智之;大熊　遼太朗;久保田　祐太郎;濵田　和幸;和田　聡;鶴谷　純司;角田　卓也, 第25回日本がん免疫学会総会, 2021年07月03日, 和歌山
• Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity, KAWAMURA Takahisa;IMAMURA Chiyo K.;KENMOTSU Hirotsugu;TAIRA Tetsuhiko;OMORI Shota;NAKASHIMA Kazuhisa;WAKUDA Kazushige;ONO Akira;NAITO Tateaki;MURAKAMI Haruyasu;MUSHIRODA Taisei;TAKAHASHI Toshiaki;TANIGAWARA Yusuke, 第18回日本臨床腫瘍学会学術集会, 2021年02月18日, Live Streaming
• EGFRチロシンキナーゼ阻害剤によるSPC-TNFトランスジェニックマウスにおける肺組織損傷とアポトーシス誘導機序の検討, 山岡　利光;大森　亨;安藤　浩一;楠本　壮二郎;本間　哲也;岸野　康成;眞鍋　亮;相良　博典;鶴谷　純司, 第60回日本呼吸器学会学術講演会, 2020年09月20日, Web開催
• Patient-reported outcomes in a randomized, optimal dose finding, phase II study of triweekly nab-paclitaxel in patients with metastatic breast cancer (the ABROAD study), KATO Hiroaki;HARA Fumikata;KITADA Masahiro;TAKAHASHI Masato;KIKAWA Yuichiro;SAKATA Eiko;NAITO Yoichi;HASEGAWA Yoshie;SAITO Tsuyoshi;IWASA Tsutomu;TSURUTANI Junji;TAIRA Naruto;TAKASHIMA Tsutomu;KASHIWABARA Kosuke;AIHARA Tomohiko;MUKAI Hirofumi, San Antonio Breast Cancer Symposium, 2019年12月12日, San Antonio
• Phase II study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with ER-positive and HER 2-negative advanced breast cancer (MERMAID) WJOG 11318 B, MASUDA Hiroko;IWASA Tsutomu;MUKOHARA Toru;TOKUNAGA Shinya;MATSUMOTO Koji;NIIKURA Naoki;SAGARA Yasuaki;MIYOSHI Yasuo;SHIMOMURA Akihiko;TAKAHASHI Masato;NAGASHIMA Takeshi;DOI Mihoko;FUTAMURA Manabu;YOSHIMURA Kenichi;TAKANO Toshimi;TSURUTANI Junji, San Antonio Breast Cancer Symposium, 2019年12月12日, San Antonio
• Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG 11418 B, NEWFLAME trial), MASUDA Jun;TSURUTANI Junji;MASUDA Norikazu;FUTAMURA Manabu;MATSUMOTO Koji;AOGI Kenjiro;TAKAHASHI Masato;IWATA Hiroji;IWASA Tsutomu;MUKOHARA Toru;YOSHIMURA Kenichi;UENO Takayuki;TAKANO Toshimi, San Antonio Breast Cancer Symposium, 2019年12月12日, San Antonio
• Addition of capecitabine to maintenance endocrine therapy after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR 1214), YOSHINAMI Tetsuhiro;NAKAYAMA Takahiro;IKEDA Masahiko;MIZUTANI Makiko;YAMAGUCHI Miki;KOMOIKE Yoshifumi;TAKASHIMA Tsutomu;YOSHIDOME Katsuhide;TSURUTANI Junji;IWAMOTO Mitsuhiko;FUJISAWA Fumie;YASOJIMA Hiroyuki;YAMAMURA Jun;MORISHIMA Hirotaka;AKI Fuminori;YAMADA Tomomi;MORITA Satoshi;MASUDA Norikazu, San Antonio Breast Cancer Symposium, 2019年12月12日, San Antonio
• [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER 2-positive metastatic breast cancer previously treated with T-DM 1: A phase 2, multicenter, open-label study （DESTINY-Breast 01, KROP Ian E;SAURA Cristina;YAMASHITA Toshinari;PARK Yeon Hee;KIM Sung-Bae;TAMURA Kenji;ANDRÉ Fabrice;IWATA Hiroji;ITO Yoshinori;TSURUTANI Junji;SOHN Joohyuk;DENDULURI Neelima;PERRIN Christophe;AOGI Kenjiro;TOKUNAGA Eriko;IM Seock-Ah;LEE Keun Seok;HURVITZ Sara;CORTES Javier;LEE Caleb;CHEN Shuquan;ZHANG Lin;SHAHIDI Javad;YVER Antoine;MODI Shanu, San Antonio Breast Cancer Symposium, 2019年12月11日, San Antonio
• A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER 2-negative metastatic breast cancer: WJOG 9917 B NEWBEAT trial, OZAKI Yukinori;MUKOHARA Toru;TSURUTANI Junji;TAKAHASHI Masato;MATSUMOTO Koji;FUTAMURA Manabu;MASUDA Norikazu;KITANO Shigehisa;YOSHIMURA Kenichi;MINAMI Hironobu, San Antonio Breast Cancer Symposium, 2019年12月11日, San Antonio
• 高齢者非小細胞肺癌に対するImmune checkpoint inhibitorの有効性に関するメタ解析, 安藤　浩一;眞鍋　亮;岸野　康成;楠本　壮二郎;山岡　利光;大森　亨;相良　博典, 第60回日本肺癌学会学術集会, 2019年12月08日, 大阪
• HER2陰性進行再発乳癌に対する治療戦略, 鶴谷　純司, 第17回日本乳癌学会近畿地方会, 2019年12月07日, 神戸
• 生命倫理審査における臨床薬理の専門性　実施側として審査を受けた経験も踏まえて, 今村　知世, 第40回日本臨床薬理学会学術総会, 2019年12月06日, 東京
• タモキシフェンpharmacogenomics 研究から学んだこと (ワークショップ4), 今村　知世, 第57回日本癌治療学会学術集会, 2019年10月24日, 福岡
• Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT., HIRATA Kenro;HAMAMOTO Yasuo;TSUCHIHASHI Kenji;KONDOH Chihiro;YAMAZAKI Kentaro;HIRONAKA Syuichi;ANDO Masahiko;IMAMURA Chiyo K.;YOSHIMURA Kenichi;MURO Kei, ESMO Congress 2019, 2019年09月27日, Barcelona
• 肝機能低下患者への抗がん薬投与 ～評価指標と推奨用量のエビデンス～ (シンポジウム18 がん薬物治療における慎重投与例への対応), 今村　知世, 第17回日本臨床腫瘍学会学術集会, 2019年07月20日, 京都
• Phase 3 study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1 in advanced HER2-positive breast cancer, YAMASHITA Toshinari;VERMA Sunil;CORTES Javier;OTANI Shoichiro;KANEKO Koji;ITO Yoshinori;TAKAHASHI Masato;INOUE Kenichi;IWATA Hiroji;JAVAD Shahidi;LEE Caleb;WANG Kongming;SAITO Kaku;MYOUBATAKE Yusuke;TSURUTANI Junji, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 2019年07月19日, 京都
• Updated results of phase 1 study of [fam-] trastuzumab deruxtecan in HER2-expressing or -mutated advanced NSCLC, NAKAGAWA Kazuhiko;DOI Toshihiko;TAKAHASHI Shunji;YOH Kiyotaka;TSURUTANI Junji;PARK Haeseong;MODI Shanu;KROP Ian E.;WAQAR Saiama N.;LI Bob T.;TAIRA Shinichiro;SAITO Kaku;FUJISAKI Yoshihiko;JIKOH Takahiro;SINGH Jasmeet;SUGIHARA Masahiro;PASI A. Janne, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 2019年07月19日, 京都
• Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC, IMAMURA Chiyo K.;KENMOTSU Hirotsugu;KAWAMURA Takahisa;OYAKAWA Takuya;ONO Akira;OMORI Shota;NAKASHIMA Kazutoshi;WAKUDA Kazushige;TAIRA Tetsuhiko;NAITO Tateaki;MURAKAMI Haruyasu;YAMAMOTO Nobuyuki;TAKAHASHI Toshiaki;TANIGAWARA Yusuke, 第17回日本臨床腫瘍学会学術集会, 2019年07月19日, 京都
• Expression of Olfactomedin-4 in pancreatic cancer and its clinical significance, OKUMA Ryotaro;KUBOTA Yutaro;HAMADA Kazuyuki;ISHIDA Hiroo;HIRASAWA Yuya;ARIIZUMI Hirotsugu;SATOH Etsuko;SHIDA Midori;WATANABE Makoto;TSURUTANI Junji;YOSHIMURA Kiyoshi;AOKI Takeshi;MURAKAMI Masahiko;NOROSE Tomoko;OHIKE Nobuyuki;TAKIMOTO Masafumi;TSUNODA Takuya;WADA Satoshi, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 2019年07月18日, 京都
• Updated results of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-low breast cancer from a large phase 1 study, TSURUTANI Junji;MODI Shanu;TAKAHASHI Shunji;PARK Haeseong;IWATA Hiroji;MURTHY Rashmi;SAGARA Yasuaki;KROP Ian E.;DOI Toshihiko;REDFERN Charles;MORENO-ASPITIA Alvaro;REDMAN Rebecca;LEE Caleb;SUGIHARA Masahiro;SAITO Kaku;FUJISAKI Yoshihiko;SATO Yuta;TAMURA Kenji, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 2019年07月18日, 京都
• Dose justification for [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer, TAKAHASHI Shunji;MODI Shanu;TSURUTANI Junji;KROP Ian E.;IWATA Hiroji;WADA Russell;YIN Ophelia;GARIMELLA Tushar;SUGIHARA Masahiro;ZHANG Lin;LEE Caleb;SAITO Kaku;KAWASAKI Yui;YVER Antoine;TAMURA Kenji, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 2019年07月18日, 京都
• Exploration of biomarkers for the choice of chemotherapy in colorectal cancer patients, FUJITA Yoshihiko;TAGURI Masataka;YAMAZAKI Kentaro;TSURUTANI Junji;SAKAI Kazuko;BOKU Narikazu;HYODO Ichinosuke;YAMANAKA Takeharu;NISHIO Kazuto, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 2019年07月18日, 京都
• Randomized Phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer: ABROAD, TAKAHASHI Masato;HARA Fumikata;KITADA Masahiro;KIKAWA Yuichiro;KATO Hiroaki;SAKATA Hideko;NAITO Yoichi;HASEGAWA Yoshie;SAITO Hiroshi;IWASA Tsutomu;TSURUTANI Junji;TAIRA Naruhito;TAKASHIMA Tsutomu;KASHIWABARA Kosuke;AIHARA Tomohiko;MUKAI Hirofumi, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 2019年07月18日, 京都
• Atezolizumab + nab-paclitaxel as first line therapy in Japanese patients with TNBC: A subgroup analysis of IMpassion130, INOUE Kenichi;SHIMOMURA Akihiko;KANEKO Koji;ITO Yoshinori;TSUGAWA Koichiro;YAMAUCHI Teruo;TSURUTANI Junji;NIIKURA Naoki;SAWAKI Masataka;DOIHARA Hiroyoshi;MIYOSHI Yasuo;HASEGAWA Ayumi;NAKAGAWA Shintaro;KURATOMI Hiroyasu;IWATA Hiroji, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 2019年07月18日, 京都
• A prospective real-world study of eribulin for HER2-negative recurrent breast cancer patients: final results, MUKAI Hirofumi;INOUE Kenichi;TAKAHASHI Masato;YAMANAKA Takashi;EKAWA Chiyomi;SAKATA Yukinori;IKEZAWA Hiroki;MATSUOKA Toshiyuki;ISHII Mika;TSURUTANI Junji, 第17回日本臨床腫瘍学会学術集会 (JSMO 2019), 2019年07月18日, 京都
• Exposure-response analysis of S-1 in patients with advanced gastric cancer, TAKEUCHI Masashi;IMAMURA Chiyo K.;BOOKA Eisuke;KASAI Hidefumi;KAWAKUBO Hirofumi;BOKU Narikazu;TANIGAWARA Yusuke;KITAGAWA Yuko, 第17回日本臨床腫瘍学会学術集会, 2019年07月18日, 京都
• 野生型KRAS遺伝子増幅によるEGFR遺伝子変異陽性(exon19del/T790M)肺腺癌細胞株のオシメルチニブ獲得耐性機序, 山岡　利光;大森　亨;相良　博典;鶴谷　純司, 第23回日本がん分子標的治療学会学術集会, 2019年06月13日, 大阪
• スペシャル・ポピュレーション（腎機能低下、肝機能低下、高齢者）へのがん薬物療法 Part 2, 今村　知世, 第52回がんプロセミナー（7大学連携個別化がん医療実践者養成プラン）, 2019年04月24日, 狭山
• EGFR遺伝子変異陽性(exon19del/T790M)肺腺癌細胞株におけるオシメルチニブ獲得耐性機序., 山岡　利光, 第59回日本呼吸器学会学術講演会, 2019年04月12日, 東京
• Exposure-toxicity analysis of unbound regorafenib and its active metabolites by dose escalation strategy with low starting dose in patients with colorectal cancer, SATAKE Hironaga;SUZUKI Takeshi;IMAMURA Chiyo K.;SUKAWA Yasutaka;MASUISHI Toshiki;KUMEKAWA Yosuke;FUNAKOSHI Shinsuke;KOTAKA Masahito;HORIE Yoshiki;KAWAI Sadayuki;OKUDA Hiroyuki;TERAZAWA Tetsuji;KONDOH Chihiro;KATO Ken;YOSHIMURA Kenichi;ISHIKAWA Hideki;HAMAMOTO Yasuo;BOKU Narikazu;TAKAISHI Hiromasa;KANAI Takanori, AACR Annual Meeting 2019, 2019年04月02日, Atlanta
• KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR., YAMAOKA Toshimitsu;OHBA Motoi;KISHINO Yasunari;KUSUMOTO Sojiro;TSURUTANI Junji;OHMORI Tohru, AACR Annual Meeting 2019, 2019年04月01日, Atlanta
• Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple studies of DS-8201a, a HER2-targeted antibody drug conjugate with a topoisomerase I inhibitor payload, POWELL Charles A.;CAMIDGE Ross D.;GEMMA Akihiko;KUSUMOTO Masahiko;BABA Tomohisa;KUWANO Kazuyoshi;BANKIER Alexander;KIURA Katsuyuki;TAMURA Kenji;MODI Shanu;TSURUTANI Junji;DOI Toshihiko;IWATA Hiroji;KROP Ian E.;ZHANG Lin;JASMEET Singh;SAITO Kaku;SHAHIDI Javad;YVER Antoine;TAKAHASHI Shunji, 41st Annual San Antonio Breast Cancer Symposium (SABCS 2018), 2018年12月08日, San Antonio
• Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study, MODI Shanu;TSURUTANI Junji;TAMURA Kenji;PARK Haeseong;SAGARA Yasuaki;MURTHY Rashmi K.;IWATA Hiroji;KROP Ian E.;DOI Toshihiko;REDFERN Charles;MORENO-ASPITIA Alvaro;REDMAN Rebecca;LEE Caleb;SUGIHARA Masahiro;FUJISAKI Yoshihiko;TAKAHASHI Shunji, 41st Annual San Antonio Breast Cancer Symposium (SABCS 2018), 2018年12月08日, San Antonio
• Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses, TAMURA Kenji;MODI Shanu;TSURUTANI Junji;TAKAHASHI Shunji;KROP Ian E.;IWATA Hiroji;WADA Russell;YIN Ophelia;GARIMELLA Tushar;SUGIHARA Masahiro;ZHANG Lin;LEE Caleb;YVER Antoine;BASELGA Jose, 41st Annual San Antonio Breast Cancer Symposium (SABCS 2018), 2018年12月08日, San Antonio
• Updated results of phase 1 study of DS-8201a in HER2-expressing or -mutated advanced non-small cell lung cancer (NSCLC), TSURUTANI Junji;PARK Haeseong;DOI Toshihiko;MODI Shanu;TAKAHASHI Shunji;NAKAGAWA Kazuhiko;KROP E Ian;WAQAR Saiama;YOH Kiyotaka;LI Bob T;TAIRA Shinichiro;JIKOH Takahiro;SINGH Jasmeet;SUGIHARA Masahiro;PASI A Janne, IASLC 19th World Conference on Lung Cancer (WCLC 2018), 2018年09月24日, Toronto